Arkolith/Insider Trading/ETON/Form 4

Krempa David

Chief Business OfficerEton Pharmaceuticals, Inc. (ETON) · full profile →Form 4 · filed Dec 12, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2025Tax withholding(F)6K$17.00$106K632K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 11, 2025Grant(A)5K—$0638K

Transaction Codes

F
Shares withheld for taxes
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-25-037745) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML